- Home
- USIO vs LUMO Comparison
USIO vs LUMO Comparison
Compare USIO & LUMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- LUMO
- Stock Information
- Founded
- USIO 1998
- LUMO 2011
- Country
- USIO United States
- LUMO United States
- Employees
- USIO N/A
- LUMO N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- LUMO Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- LUMO Health Care
- Exchange
- USIO Nasdaq
- LUMO Nasdaq
- Market Cap
- USIO 37.8M
- LUMO 37.4M
- IPO Year
- USIO N/A
- LUMO N/A
- Fundamental
- Price
- USIO $1.47
- LUMO $4.32
- Analyst Decision
- USIO Strong Buy
- LUMO Buy
- Analyst Count
- USIO 2
- LUMO 4
- Target Price
- USIO $5.00
- LUMO $9.38
- AVG Volume (30 Days)
- USIO 81.8K
- LUMO 85.1K
- Earning Date
- USIO 11-06-2024
- LUMO 11-07-2024
- Dividend Yield
- USIO N/A
- LUMO N/A
- EPS Growth
- USIO N/A
- LUMO N/A
- EPS
- USIO 0.13
- LUMO N/A
- Revenue
- USIO $81,027,258.00
- LUMO $2,205,000.00
- Revenue This Year
- USIO $4.13
- LUMO $184.11
- Revenue Next Year
- USIO $13.76
- LUMO N/A
- P/E Ratio
- USIO $11.08
- LUMO N/A
- Revenue Growth
- USIO N/A
- LUMO 26.94
- 52 Week Low
- USIO $1.30
- LUMO $1.37
- 52 Week High
- USIO $2.00
- LUMO $4.58
- Technical
- Relative Strength Index (RSI)
- USIO 54.32
- LUMO 55.26
- Support Level
- USIO $1.40
- LUMO $4.30
- Resistance Level
- USIO $1.55
- LUMO $4.39
- Average True Range (ATR)
- USIO 0.06
- LUMO 0.09
- MACD
- USIO 0.00
- LUMO -0.03
- Stochastic Oscillator
- USIO 61.90
- LUMO 32.50
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for the Output Solutions operations.
About LUMO Lumos Pharma Inc.
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.